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PHARMACOKINETICS AND 
DRUG DISPOSITION 
Role of intestinal I?glycoprotein (mdrl) 
in interpatient variation in the oral 
bioavailability of cyclosporine 
Interpatient differences in the oral clearance of cyclosporine (INN, ciclosporin) have been partially attrib- 
uted to variation in the activity of a single liver enzyme termed CYP3A4. Recently it has been shown that 
small bowel also contains CYP3A4, as well as P-glycoprotein, a protein able to transport cyclosporine. To 
assess the importance of these intestinal proteins, the oral pharmacokinetics of cyclosporine were measured 
in 25 kidney transplant recipients who each had their liver CYP3A4 activity quantitated by the intravenous 
[‘“C-N-methyl]-erythromycin breath test and who underwent small bowel biopsy for measurement of 
CYP3A4 and P-glycoprotein. Forward multiple regression revealed that 56% (i.e., ra = 0.56) and 17% of 
the variability in apparent oral clearance [log (dose/area under the curve)] were accounted for by variation 
in liver CYP3A4 activity (p C 0.0001) and intestinal P-glycoprotein concentration (p = 0.0059), respec- 
tively. For peak blood concentration, liver CYP3A4 activity accounted for 32% (p = 0.0002) and I?- 
glycoprotein accounted for an additional 30% (p = 0.0024) of the variability. Intestinal levels of CYP3A4, 
which varied tenfold, did not appear to influence any cyclosporine pharmacokinetic parameter examined. 
We conclude that intestinal P-glycoprotein plays a significant role in the first-pass elimination of cyclo- 
sporine, presumably by being a rate-limiting step in absorption. Drug interactions with cyclosporine 
previously ascribed to intestinal CYP3A4 may instead be mediated by interactions with intestinal 
P-glycoprotein. (Clin Pharmacol Ther 1997;62:248-60.) 
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Cyclosporine (INN, ciclosporin) is the primary 
immunosuppressant used in solid organ transplan- 
tation. Its use has greatly improved allograft survival 
by decreasing the frequency of both acute T-cell- 
mediated cellular rejection and chronic rejection.‘” 
However, its clinical use is complicated by its narrow 
therapeutic index; the daily dose of cyclosporine 
required to suppress organ rejection in some pa- 
tients can cause renal and neurologic toxicity in 
others. The clinical dithculties presented by this nar- 
row therapeutic index are compounded by the exis- 
tence of large interpatient differences in the oral 
bioavailability of cyclosporine.4,5 This is reflected in 
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the observation that the daily dose of cyclosporine 
required to suppress rejection while avoiding toxic- 
ity varies at least tenfold among transplant recipi- 
ents.6 
Recently considerable insight has been obtained 
regarding the mechanisms that may underlie the 
marked variability in the oral pharmacokinetics of 
cyclosporine. The enzyme principally responsible for 
cyclosporine metabolism is a cytochrome P450 
termed CYP3A4.7-9 This is the major cytochrome 
P450 enzyme present in the liver.” There are 
marked interindividual differences in the concentra- 
tion and activity of hepatic CYP3A4.1°-13 Thummel 
et a1.14 showed that variation in liver content of 
CYP3A4 in liver transplant recipients accounted for 
66% of the interpatient variation in the clearance of 
intravenously administered cyclosporine. 
In contrast, variation in liver CYP3A4 activity 
does not appear to account for a majority of the 
interpatient variability in pharmacokinetics when cy- 
closporine is administered orally. In a previous study 
we showed that variation in liver CYP3A4 activity, 
as measured by the intravenous “C-erythromycin 
breath test (ERMBT),l’ predicted only about one 
third of the inter-patient variability in the oral clear- 
ance (CL/F) of cyclosporine in kidney transplant 
patients.16 The basis for the remaining variation in 
CL/F is unknown. However, one possible explana- 
tion may be related to the abundant expression of 
CYP3A4 in small bowel epithelial cells (entero- 
cytes).17,18 Several studies have indicated that intes- 
tinal CYP3A4 is responsible for significant first-pass 
metabolism of orally administered cyclosporine.19-22 
We have found that the enterocyte content of 
CYP3A4 protein correlates with its catalytic activity 
(midazolam l’-hydroxylation) and varies up to ten- 
fold among patients.13 Furthermore, intestinal and 
liver CYP3A4 expression do not appear to be coor- 
dinately regulated.i3 Hence it is possible for an in- 
dividual to have relatively high liver CYP3A4 activ- 
ity while having relatively low intestinal CYP3A4 
activity or to have relatively low liver CYP3A4 ac- 
tivity while having relatively high intestinal CYP3A4 
activity. If the extent of intestinal first-pass metabo- 
lism is proportional to the intestinal content of 
CYP3A4, it would seem to be likely that variation in 
intestinal CYP3A4 activity could account for a por- 
tion of the unexplained variation in the oral phar- 
macokinetics of cyclosporine. 
Another potential source of variation in oral cy- 
closporine pharmacokinetics may be related to the 
expression of P-glycoprotein, the m&l gene prod- 
uCt,23 in the intestine. P-glycoprotein is a versatile 
transporter that is able to pump a wide variety of 
xenobiotics including cyclosporine.24-28 In the intes- 
tine, P-glycoprotein is located almost exclusively 
within the brush border on the apical (luminal) 
surface of the enterocyte where it pumps xenobiotics 
from the cytoplasm to the exterior of the cell (i.e., 
from the enterocyte back into the intestinal 
lumen).29”2 We recently showed that, as with 
CYP3A4, there is significant interindividual varia- 
tion in the intestinal expression of P-glycoprotein.33 
Given its transport function, high intestinal levels of 
P-glycoprotein may interfere with drug absorption 
and contribute to the variation in cyclosporine oral 
pharmacokinetics. 
To directly test the hypothesis that the levels of 
intestinal CYP3A4 and P-glycoprotein expression 
are important determinants of oral cyclosporine bio- 
availability, we measured the pharmacokinetics of 
orally administered cyclosporine in stable kidney 
transplant recipients. Each patient had his or her 
liver CYP3A4 activity measured with the ERMBT 
and underwent endoscopy to obtain small bowel 
biopsy specimens for determination of the entero- 
cyte content of CYP3A4 and P-glycoprotein. 
METHODS 
Subjects 
Statistical power analysis indicated that 20 pa- 
tients at steady state would be needed to provide an 
85% chance of detecting a significant correlation 
between cyclosporine pharmacokinetics and intesti- 
nal CYP3A4 or P-glycoprotein, if the true respective 
correlation coefficients were 0.6 or greater. In our 
previous study of cyclosporine pharmacokinetics,i6 
20% (4 of 20) of the subjects entered in the study 
were not at steady state, when steady state was 
defined as having initial and 24-hour cyclosporine 
(trough) blood levels that differed by less than 25%. 
For our current study we therefore recruited 25 
subjects from among the stable kidney transplant 
recipients monitored in the University of Michigan 
Medical Center nephrology clinic. 
To be included in the study, patients had to be at 
least 18 years old and be considered medically sta- 
ble. Transplantation must have occurred at least 6 
months before the study. In addition, each patient 
had to be taking cyclosporine as a single daily dose 
and, to increase the likelihood of recruiting patients 
at steady state, must not have had an adjustment in 
cyclosporine dose within 30 days of study participa- 
tion. All patients were receiving the Sandimmune 
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Table I. Patient characteristics 
Patient 
No. Kidney dbease Age Sex 
Cyclosporine 
dose ERMBT Enterocyte Enterocyte 
(mg/kg/day) (% 14C/hr) CYP3A4 * P-glycoprotein * 
1 
2 
3 
4 
5 
6 
7t 
8 
9 
m 
11 
12 
13 
14 
15-i 
16 
174 
18 
19 
20 
21 
22 
231 
24.3 
25 
Diabetes 
Immunogiobulin A nephropathy 
Diabetes 
Chronic pyelonephritis 
Chronic pyelonephritis 
Lupus 
Diabetes 
Chronic glomernlonephritis 
unknown 
Membranoproliferative 
glomerulonephritis 
Lupus 
Chronic glomernlonephritis 
Polycystic kidney disease 
Chronic pyelonephritis 
Obstruction 
Amyloidosis 
Polycystic kidney disease 
Diabetes 
Chronic pyelonephritis 
Polycystic kidney disease 
Chronic glomernlonephritis 
Diabetes 
Chronic pyelonephritis 
Diabetes 
Chronic pyelonephritis 
Mean (all patients, n = 24) 43 -e 13 
Mean (patients analyzed, n = 19) 43 ? 13 
67 Male 2.58 2.77 90 2 27 89 k 35 
34 Male 7.85 2.64 92 -+ 37 131 rf: 42 
58 Male 2.67 1.69 96 -c 26 153 + 10 
36 Male 3.18 3.80 87 2 22 31 + 10 
38 Female 5.98 3.00 58 ? 13 81 + 23 
38 Female 6.04 2.78 162 2 25 263 + 75 
64 Male 6.22 4.39 94 + 18 1OOt28 
30 Male 5.35 2.67 104 + 31 103 + 33 
54 Male 3.48 3.08 66 t 11 40 t 13 
64 Male 4.34 3.36 89 t 15 45 ” 7 
21 Female 5.73 4.26 692 17 63 + 14 
24 Female 6.28 2.59 145 ‘-’ 24 88k 18 
60 Male 4.38 2.78 101 2 25 94 + 29 
42 Male 4.79 2.46 90 2 36 117 2 23 
24 Male 4.48 1.68 127 ?z 23 72 + 13 
45 Male 4.83 2.64 151 t 42 114 + 20 
63 Male 2.10 1.93 78 2 23 47 + 20 
34 Female 6.09 3.39 37 +- 13 55 + 11 
47 Male 4.06 1.68 32 +- 13 64 + 22 
64 Male 2.35 1.66 302 +- 123 70 + 6 
45 Male 5.24 3.04 72 ? 26 43 t 12 
48 Male 4.62 2.25 70 4 15 57 ” 14 
46 Female 3.55 4.72 111 2 42 65 rf: 26 
38 Female 2.49 2.08 119 f 20 48 2 8 
23 Male 7.34 2.50 56 2 14 117 + 14 
- 
- 
4.57 + 1.59 2.73 + 0.79 100 + 54 85 + 50 
4.89 + 1.57 2.72 t 0.66 99 + 60 93 2 53 
Data are mean values 2 SD. 
‘Enterocyte CYP3A4 and P-glycoprotein are expressed as the ratio of the computer-determined densitometric value of the protein of interest relative to viUin 
(see Methods). 
tPatient excluded from study because he was taking phenytoio, a known potent CYP3A4 inducer. 
*Patients excluded from analysis because they were not at steady state. 
(Sandoz Pharmaceuticals, East Hanover, N.J.) for- 
mulation of cyclosporine. At the time this study was 
performed, the microemulsion formulation of cyclo- 
sporine, Neoral, was not in use at our institution. 
Patients were also excluded from consideration if 
they were pregnant, were allergic to erythromycin, 
had active peptic ulcer disease, had an episode of 
rejection within 30 days of participation in the study, 
or were taking medications known to be potent 
inducers or inhibitors of CYP3A4 activity. No con- 
sideration was given to the primary kidney disease, 
race, or gender of the patients. 
A summary of patient characteristics is shown in 
Table I. Three of the patients (patients 6, 20, and 
21) had participated in our earlier study.r6 Most of 
the patients were receiving prednisone, azathio- 
prine, and cyclosporine for immunosuppression. 
Many were also receiving multiple concomitant 
medications (medication information is available 
from the authors on request). Written informed 
consent was obtained from all subjects. This study 
was approved by the Institutional Review Board of 
the University of Michigan. 
Experimental design 
Patients were admitted to the University of Mich- 
igan General Clinical Research Center (GCRC) for 
the duration of their 3-day involvement in the study. 
To maintain individuals at steady state, every effort 
was made to continue patients on their usual diets. 
The GCRC dietary staff planned menus to match 
the subjects’ usual dietary content of fat, protein, 
and carbohydrate determined from computer anal- 
ysis (Food Processor II program, Esha Research, 
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Salem, Ore.) of detailed diet diaries filled out by 
each subject for the 3 days before admission. 
Patients were admitted to the GCRC the evening 
before the start of the study. The following morning 
the subjects took their routine dose of cyclosporine 
in their usual manner (i.e., at the same time of day, 
with the same liquid, and in the same relationship to 
breakfast). Blood samples (10 ml) were obtained at 
0, 1/2, 1, lV2, 2, 2X, 3, 31/2, 4, 5, 6, 8, 10, 12, 18, and 
24 hours after cyclosporine administration and were 
frozen. After completion of the study, the samples 
were thawed and the whole blood was analyzed for 
parent cyclosporine by HPLC?l 
Immediately after the 24-hour blood sample was 
collected, each subject was given the ERMBT. After 
finishing the breath test, each subject again took his 
or her usual cyclosporine dose in his or her custom- 
ary manner and ate breakfast; thereafter, no addi- 
tional oral intake was allowed. Four hours after 
breakfast, each subject underwent upper endoscopy 
to obtain small bowel biopsy specimens for determi- 
nation of intestinal CYP3A4 and P-glycoprotein 
content. After they completely recovered from the 
sedation for the endoscopy, patients were dis- 
charged from the GCRC. 
Pharmacokinetic analysis 
Subjects whose O-hour and 24-hour cyclosporine 
levels varied by more than 25% were not considered 
to be at steady state and were excluded from anal- 
ysis. The total area under the observed blood con- 
centration-time curve (AUC) was calculated by use 
of the linear and logarithmic trapezoidal method in 
the rising and declining phases of cyclosporine con- 
centrations, respectively. The apparent CL/F was 
calculated by dividing the cyclosporine dose by the 
AUC. The drug half-life (t& was determined by the 
slope of the log-linear terminal phase of the curve. 
The peak blood concentration (C,,), time to peak 
(tmax), and trough blood level (C,,) were deter- 
mined directly from the blood concentration versus 
time data. 
We have shown previously that the ERMBT re- 
sult best correlates with the body weight-corrected 
pharmacokinetic parameters of a drug.13 All phar- 
macokinetic parameters were therefore normalized 
to the dose of cyclosporine, expressed in milligrams 
per kilogram. 
Erythromycin breath test 
The in vivo catalytic activity of hepatic CYP3A4 
can be conveniently and noninvasively estimated as 
the rate of 14C02 exhaled after an intravenous test 
dose of [14C-N-methyl]-erythromycin. This test is 
based on the observation that CYP3A4 exclusively 
catalyzes the N-demethylation of erythromycin in 
liver microsomes34 and that the carbon atom in the 
resulting formaldehyde should largely appear in the 
breath as carbon dioxide.35 We have shown that the 
ERMBT result correlates well with the liver content 
of CYP3A4 in patients undergoing liver transplant 
and does not at all correlate with the liver content of 
five other major liver P450~.~~ 
The ERMBT was administered as described pre- 
viously. 34 Breath test results were expressed as the 
percentage of administered 14C that was exhaled 
during the first hour after the injection of erythro- 
mycin34 estimated from the rate of radiolabel exha- 
lation at 20 minutes, as described previously.37 
Intestinal CYP3A4 and P-glycoprotein analysis 
&z&copy. Each patient fasted for 4 hours after 
breakfast and then underwent upper intestinal en- 
doscopy (5 hours after the ERMBT). Patients were 
sedated with intravenous midazolam (Roche Phar- 
maceuticals, Nutley, N.J.) and meperidine (INN, 
pethidine) (Sanofi Winthrop Pharmaceuticals, New 
York, N.Y.), and a fiberoptic endoscope was passed 
into the small intestine (distal duodenum) where 
five mucosal biopsy specimens (approximately 5 mg 
wet weight each) were obtained from the second 
portion of the duodenum. The biopsy specimens 
were placed directly in ice cold solution D [0.05 
mol/L Tris hydrochloride, 20% glycerol, 2 mmol/L 
ethylenediaminetetraacetic acid, and 1 mmol/L phe- 
nylmethylsulfonyl fluoride38], immediately homoge- 
nized in a glass tissue grinder, and snap frozen in 
liquid nitrogen. Samples were stored at -80” C until 
analyzed. 
cyP3A4 and P-gljroprotein immunoblotting. Immu- 
noblots were performed as described previously with 
minor modifications.13 Fifteen micrograms of whole 
biopsy homogenate was electrophoresed and trans- 
ferred to nitrocellulose. We have found that, com- 
pared with whole homogenate, more than 80% of 
CYP3A4 immunoreactive protein was lost during 
preparation of the S9 fraction used in our previous 
study (Lown et a1.,13 and data not shown). In addi- 
tion, use of whole homogenate allowed us to se- 
quentially probe a single blot for CYP3A4 (a micro- 
somal protein), P-glycoprotein (a membrane bound 
protein), and villin (a cytosolic protein). 
The blots were sequentially incubated with 13-7- 
10, a mouse monoclonal antibody specific for human 
252 Lown et al. CLINICAL PHARMACOLOGY &THERAPEUTICS SEPTEMBER 1997 
CYP3A proteins17939,40; a mouse monoclonal anti- 
body raised against chick villin that crossreacts with 
human villin (Chemicon International, Temecula, 
Calif.); and MDR-Abl, a rabbit polyclonal antibody 
to human P-glycoprotein (Oncogene Science, 
Uniondale, N.Y.). 
The 13-7-10 antibody reacts with all CYP3A pro- 
teins. However, because CYP3A4 is the major 
CYP3A protein expressed in the small intestine,13’18 
the amount of antibody bound on the immunoblots 
will primarily reflect CYP3A4 protein levels. Essen- 
tially no mdd is expressed in human small intes- 
tine 33,41,42 so protein detected by the MDR-Abl 
antibody on the immunoblots corresponds to the 
mdrl gene product, P-glycoprotein. 
The blots were developed with a chemilumines- 
cence kit (Amersham, Arlington Heights, Ill.) and 
exposed to Hyperfilm ECL (Amersham) for differ- 
ent durations to obtain appropriate exposures for 
CYP3A4 (approximately 3 seconds), villin (approx- 
imately 15 seconds), and P-glycoprotein (approxi- 
mately 3 minutes). 
Immunoblot protein concentrations were deter- 
mined by computer-aided densitometry. Gptical den- 
sities were performed on a Macintosh computer (Ap- 
ple Computer, Inc., Cupertino, Calif.) with use of the 
public domain program NIH Image (developed at the 
U.S. National Institutes of Health and available on the 
Internet at http://rsb.info.nih.gov/nih-image/). Individ- 
ual exposures were scanned into binary images with a 
Scan Jet IIc color scanner (Hewlett-Packard, Greeley, 
Cola.). Optical densities were converted to quantita- 
tive numbers by comparison with slot blots of serial 
dilutions of purified CYP3A4 protein that had been 
processed simultaneously with the immunoblots and 
exposed on the same fihns and for the same duration 
as the protein being quantitated. This allowed for cor- 
rection of the nonlinearity of ECL light output and 
ECL Hyperfihn. 
Correction for interbiopsy variation of enterocyte 
content. CYP3A4 and P-glycoprotein are expressed 
exclusively in mature enterocytes in the intes- 
tine.‘7,18,29 These enterocytes represent only a small 
fraction of the cells obtained in an intestinal biopsy 
specimen. The content of mature enterocytes varies 
widely between biopsy specimens, even among bi- 
opsy specimens obtained from a single individual.13 
For example, a deep mucosal biopsy specimen 
would contain a relatively low proportion of entero- 
cytes per milligram of biopsy homogenate and after 
blotting would appear to have a lower concentration 
of P-glycoprotein and CYP3A4 protein per milli- 
gram of protein than a shallow biopsy specimen 
obtained from the same individual.13 
We have found that the enterocyte content of 
villin, a constitutively expressed, enterocyte-specific 
protein,43 may be used to control for the variation in 
biopsy content of mature enterocytes.13,44 Therefore 
enterocyte levels of CYP3A4 and P-glycoprotein 
protein were expressed as a ratio with the villin 
content of the same sample (i.e., CYP3A4/villin and 
P-glycoprotein/villin). These villin-corrected values 
provide a relative measure of enterocyte concentra- 
tion and, for the sake of simplicity, have been 
termed enteroqte concentration in the text. 
Immunoblots of P-glycoprotein and CYP3A4 
were repeated a total of four and seven times, re- 
spectively; Final values were calculated from the 
arithmetic mean of all of the runs, with any outlying 
points (greater than 2 standard deviations from the 
mean for that sample) omitted. Only seven of the 
140 CYP3A4 measurements and five of the 80 P- 
glycoprotein measurements were discarded. 
Additional laboratory studies 
Blood hematocrit, serum creatinine, aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase, total bilirubin, total 
cholesterol, and albumin were determined from 
blood drawn at the time of the patient’s admission to 
the GCRC. 
Statistical analysis 
Statistical analysis of the data was performed with 
use of StatView 4.5 (Abacus Concepts Inc., Berke- 
ley, Calif.) and SAS (SAS Institute Inc., Cary, N.C.). 
All values are expressed as mean -t- SD. Values for 
cyclosporine clearance, C,,, Cmin, and dose were 
log-transformed to normalize their distribution for 
statistical analysis. Values for CYP3A4/villin and 
P-glycoprotein/villin were log-transformed to nor- 
malize their variances. It should be noted that use of 
nontransformed data in our analyses did not alter 
any of our findings; allp values remained significant. 
Independent variables that significantly influenced 
pharmacokinetic parameters were identified by use 
of linear regression with forward variable selection. 
Comparisons of means were determined with use of 
two-tailed t tests. Results were considered to be 
significant whenp < 0.05. 
RESULTS 
All 25 of the stable kidney transplant patients 
enrolled in the study completed the protocol. Data 
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Patient Number 1 3 3 4 5 6 7 8 9 11 13 13 14 16 18 19 30 21 ” ‘5 -1 I 
Fig. 1. Representative immunoblot of intestinal biopsy protein from the 19 subjects included 
in the analysis and the patient excluded because of treatment with phenytoin (subject 7, Table 
I). After sequential incubation with the three primary antibodies (see Methods), the blot was 
exposed to ECL Hyperfilm for different durations to obtain appropriate exposure for CYP3A4 
(3 seconds), villin (15 seconds), and P-glycoprotein (3 minutes). Protein levels were quanti- 
tated by comparison to serial dilutions of purified CYP3A4 developed simultaneously and 
exposed for identical time intervals. 
on these patients are summarized in Table I. After 
the completion of the study, we discovered that one 
of the patients (patient 7) had been taking pheny- 
toin, a potent inducer of liver CYP3A4.45 This pa- 
tient therefore did not meet our original entry cri- 
teria, so he was excluded from all analyses. 
However, inclusion or exclusion of this patient did 
not significantly alter any of the observations made 
from the data set (not shown). Of the remaining 24 
patients, five patients had O-hour and 24-hour blood 
concentrations (trough levels) that differed by more 
than 25% (range, 29% to 683%). These patients did 
not meet our predetermined definition of steady 
state (which would cause their cyclosporine pharma- 
cokinetic parameters to be inaccurate) and were 
therefore excluded from the pharmacokinetic anal- 
yses. 
The enterocyte concentration of CYP3A4 (ex- 
pressed as the CYP3A4 to villin ratio) varied almost 
tenfold among both the 24 subjects who met the 
study entrance criteria and the final 19 patients 
(Table I and Fig. 1). There was no significant cor- 
relation between the levels of enterocyte CYP3A4 
concentration and liver CYP3A4 activity as mea- 
sured by the ERMBT (r = 0.17,~ = 0.43), confirm- 
ing our previous observation that liver and intestinal 
CYP3A4 are not coordinately expressed.13 Entero- 
cyte CYP3A4 levels were also not significantly cor- 
related with age (p = 0.44) and were similar among 
men and women (mean, 100.6 and 94.2, respective- 
ly>- 
There was also substantial interpatient variation 
in intestinal P-glycoprotein expression. The entero- 
cyte concentration of P-glycoprotein (P-glycoprotein/ 
villin ratio) was found to vary more than eightfold 
among both the 24 subjects who met the study en- 
trance criteria and the final 19 patients (Table I and 
Fig. 1). There was no significant correlation between 
the level of enterocyte concentration of P-glycoprotein 
and either intestinal or liver CYP3A4 levels (r = 0.30, 
p = 0.15 and r = -0.26, p = 0.23, respectively). En- 
terocyte P-glycoprotein levels were also not signili- 
cantly correlated with age @ = 0.67) and were similar 
between men and women (mean, 87.4 and 109.9, re- 
spectively). 
There were large (fourfold to sevenfold) differ- 
ences in the AUC, C,,, t,,, and CL/F of cyclo- 
sporine among the 19 patients at steady state. The 
values of these pharmacokinetic parameters are 
summarized in Table II. We found a highly signifi- 
cant correlation between the log-transformed ap- 
parent CL/F of cyclosporine [log(dose/AUC), in li- 
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Table II. Pharmacokinetic parameters of oral cyclosporine in the 19 patients at steady state 
Patient Apparent CL/F AUC c 
(ng72) 
Gill 
No. (Llhrlkg) (pg - hrlL) Wml) 
1 
2 
3 
4 
5 
i 
9 
11 
12 
13 
14 
16 
18 
19 
20 
21 
22 
25 
1.13 2290 475.2 36.7 
1.42 5549 601.4 105.8 
0.99 2691 341.9 63.0 
1.97 1612 339.3 32.6 
2.36 2537 355.4 49.8 
1.87 3237 350.8 67.0 
1.73 3089 476.9 52.5 
1.39 2499 293.4 52.2 
2.48 2305 241.5 37.9 
1.48 4229 766.6 50.3 
1.19 3662 492.3 75.7 
1.91 2503 401.5 44.2 
1.45 3335 378.3 59.6 
1.26 4826 1055.6 64.9 
0.57 7186 849.6 64.4 
0.64 3706 550.9 57.9 
1.27 4117 624.4 52.8 
1.16 3996 655.6 68.4 
1.45 5059 704.2 52.2 
2 
3.5 
5 
1.5 
6 
5 
2 
6 
12 
1.5 
5 
5 
5 
1 
2 
4 
1.5 
5 
Mean 1.46 3602 523.9 57.3 3.9 
SD 0.51 1360 212.7 16.4 2.6 
WF, Apparent oral clearance, dose/AUC; AUC, area under the blood concentration-time curve; C,,, peak blood concentration; C&, trough blood level; 
C,, time to reach C,. 
ters per hour per kilogram] and the erythromycin 
breath test result in the expected direction (r = 0.75, 
p = 0.0003). That is, patients with the highest liver 
CYP3A4 activity, as measured by the erythromycin 
breath test, tended to have the highest apparent 
CL/l? values. Interpatient variation in the erythro- 
mycin breath test accounted for 56% (i.e., ? = 0.56) 
of the variability in CL@. Age and total cholesterol 
were also significantly correlated with the log of 
cyclosporine CL/F (r = -0.63, p = 0.0042 and r = 
-0.48, p = 0.038, respectively). No significant cor- 
relation was observed between cyclosporine CL/P 
and any of the other variables examined (intestinal 
CYP3A4 or P-glycoprotein, blood hematocrit, se- 
rum creatinine, AST, ALT, alkaline phosphatase, 
total bilirubin, and albumin). 
A stepwise forward regression analysis was per- 
formed with the log-transformed cyclosporine CL@ 
as the dependent variable and the erythromycin 
breath test result, log of the intestinal biopsy con- 
centrations of CYP3A4 and P-glycoprotein, blood 
hematocrit, serum creatinine, AST, ALT, alkaline 
phosphatase, total bilirubin, total cholesterol, and 
age as the independent variables. In the first step of 
the regression, as expected, the ERMBT result was 
selected as most predictive of variation in cyclospor- 
ine CWF. Once the ERMBT result was incorpo- 
rated into the model, the enterocyte content of P- 
glycoprotein (log P-glycoprotein/villin) was selected 
as most predictive of the variation in CUF. P- 
glycoprotein was positively correlated with CL/P, i.e. 
the higher the intestinal P-glycoprotein level, the 
higher the CL/P. The addition of intestinal P- 
glycoprotein concentration improved the predictive- 
ness of the model from an ? of 0.56 (for ERMBT 
values alone) to an 12 of 0.73. Variation in intestinal 
P-glycoprotein therefore accounted for approxi- 
mately 17% of the observed variation in CL/P. Once 
the erythromycin breath test and enterocyte P- 
glycoprotein level were incorporated into the model, 
none of the other independent variables examined, 
including enterocyte CYP3A4 levels, were signifi- 
cantly predictive. In fact, the enterocyte CYP3A4 
levels failed to approach signiticance in any step of 
the forward regression analysis. Both the ERMBT 
result (p < 0.0001) and intestinal P-glycoprotein 
expression (p = 0.0059) were highly significant in 
the final model that predicted CL/P (r = 0.85; p < 
0.0001): 
log (CL@) = 0.231 (ERMBT) 
+ 0.337 (log P-glycoproteixQvillin) - 1.137 
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A graph showing the observed clearance values ver- 
sus those predicted by the above model is shown in 
Fig. 2, A. 
We next determined those variables that corre- 
lated with the C,, corrected for the administered 
cyclosporine dose (C,Jdose). There was a signifi- 
cant inverse correlation between the log of C,,.,J 
dose ratio and the ERMBT result in the expected 
direction (r = -0.56, p = 0.012). Patients with the 
highest hepatic CYP3A4 activity values tended to 
have the lowest maximal levels of cyclosporine. Age 
and cholesterol also significantly correlated with log 
C,.Jdose levels (r = 0.56, p = 0.013 and r = 0.50, 
p = 0.028, respectively). There was no significant 
correlation between C,ddose and any other vari- 
able examined, including enterocyte content of 
CYP3A4 and P-glycoprotein. 
Stepwise forward regression analysis again se- 
lected the ERMBT result as the most significant 
independent predictor of peak cyclosporine levels. 
The next step of the regression incorporated the log 
of the enterocyte content of P-glycoprotein into the 
model. No other independent variables, including 
enterocyte CYP3A4 levels, were selected as signifi- 
cant in the regression analysis. The addition of en- 
terocyte P-glycoprotein into the model accounted 
for an additional 30% of the variability in C,,, 
because the ? of the model improved from 0.318 to 
0.624. The ERMBT result (p = 0.0002) and entero- 
cyte P-glycoprotein expression @ = 0.0024) were 
highly significant in the final model that predicted 
cm, (r = 0.79,p = 0.0004): 
= -0.236 (ERMBT) - 0.533 (log P-glycoprotein) + 3.686 
The relationship between the observed log C,.J 
dose values versus those predicted by the above 
model is shown in Fig. 2, B. 
When the dose adjusted cyclosporine trough val- 
ues were analyzed, we found a significant inverse 
correlation between the log-transformed trough lev- 
els (log trough/dose) and the ERMBT result (r = 
-0.61, p = 0.0053). Hence, as expected, the higher 
the ERMBT result was, the lower the cyclosporine 
trough level was for a given dose. Intestinal 
CYP3A4 and P-glycoprotein content did not signif- 
icantly predict cyclosporine trough levels. 
Fig. 2. Comparisons of the observed versus predicted val- 
ues from the multiple regression equations for cyclospor- 
ine (INN, ciclosporin) clearance (A) and peak blood con- 
centration (C,,) (B). Both regression models were 
derived from the erythromycin breath test results and 
intestinal P-glycoprotein measurements. See Results sec- 
tion for the specific predictive equations. 
maximal blood cyclosporine level (&ax) and any of 
the variables examined. 
DISCUSSION 
The t,,2 was not significantly correlated with the The results of this study confirm the important 
ERMBT result (r = 0.12, p = 0.64), intestinal contribution of hepatic CYP3A4 to interpatient dif- 
CYP3A4 levels (r = 0.21, p = 0.40), or intestinal ferences in cyclosporine pharmacokinetics. The 
P-glycoprotein levels (r = 0.35,~ = 0.14). We also ERMBT result was highly correlated with the ap- 
found no significant correlation between the time to parent CIJF of cyclosporine and accounted for 56% 
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of the variation in CL/F we observed. The correla- 
tion with CL/F was in a positive direction, consistent 
with the expectation that patients with higher he- 
patic CYP3A4 activity values have greater rates of 
cyclosporine metabolism and hence higher cyclo- 
sporine clearance values. The ERMBT result was 
also highly correlated with the dose-adjusted C,, 
and trough blood levels of cyclosporine, accounting 
for 32% and 37% of the variation in C,, and 
trough level, respectively. In this case the correla- 
tions were inverse, as expected, given that higher 
levels of hepatic CYP3A4 should lead to lower 
blood levels. 
The primary goal of this study was to determine 
whether interpatient differences in intestinal 
CYP3A4 or P-glycoprotein expression also contrib- 
ute to variability in cyclosporine oral pharmacoki- 
netics. Given the recent evidence indicating that a 
significant fraction of orally administered cyclospor- 
ine is metabolized in the intestine,19-22 we had an- 
ticipated that variation in intestinal CYP3A4 would 
account for a significant portion of the variation in 
oral cyclosporine pharmacokinetics. However, we 
did not find this to be the case. It is possible that a 
true correlation exists with intestinal CYP3A4 that 
was not detected by our study. This could have 
occurred if the level of CYP3A4 we measured in the 
proximal small bowel did not correlate with the total 
mass of intestinal CYP3A4. It is possible that prox- 
imal intestinal CYP3A4 (and P-glycoprotein levels) 
do not correlate with levels in the distal intestine, 
where the majority of cyclosporine absorption oc- 
curs. Alternatively, it is possible that intestinal 
CYP3A4 activity might be incorporated into the 
ERMBT result, in which case the presence of 
the ERMBT in the regression model may have 
prevented the detection of a true correlation with 
intestinal CYP3A4 levels (i.e., the enterocyte 
CYP3A4 measurements would not have been an 
independent variable). This idea is supported by the 
recent observation that intravenously administered 
midazolam is significantly metabolized in the intes- 
tine.P6 However, we found no correlation between 
the ERMBT result and intestinal CYP3A4 levels. In 
addition, we have shown that there is an approxi- 
mately 80% decrease in the ERMBT result during 
the anhepatic phase of a liver transplant opera- 
tion,47 suggesting that any intestinal contribution to 
the ERMBT result should be small. Finally, in a 
recent study similar in design to this one, we found 
that interindividual variation in C,, observed after 
the oral administration of felodipine did correlate 
significantly with the enterocyte concentration of 
CYP3A4 measured in small bowel biopsy speci- 
mens.44 
The above considerations not withstanding, our 
observation that the tenfold variation in enterocyte 
content of CYP3A4 had no clear effect on oral 
cyclosporine pharmacokinetics does not support our 
previous hypothesis that induction or inhibition of 
intestinal CYP3A4 largely accounts for drug inter- 
actions involving cyclosporine.18919 What did emerge 
from our analyses was a highly significant correla- 
tion between enterocyte P-glycoprotein content and 
cyclosporine oral pharmacokinetics in stepwise 
multiple regression analyses. There were no signifi- 
cant direct correlations between enterocyte P- 
glycoprotein levels and any of the cyclosporine phar- 
macokinetic parameters examined. However, this 
appeared to be the result of the large contribution of 
variation in hepatic CYP3A4 (as measured by the 
ERMBT). Enterocyte P-glycoprotein levels became 
highly significant in predicting variations in CL/F 
once variation in the ERMBT results had been 
taken into account in a stepwise forward regression 
analysis (Fig. 2, A). The correlation between P- 
glycoprotein levels and CL/F was in the expected 
direction: the higher the enterocyte P-glycoprotein 
content, the higher the apparent CL/F of cyclospor- 
ine. The final model that incorporated the ERMBT 
result and the intestinal biopsy measurements of 
P-glycoprotein levels accounted for 73% of the 
variability in CL/F observed in our stable kidney 
transplant population. Enterocyte levels of P- 
glycoprotein alone were able to account for 17% of 
dose-adjusted CL/F variation. Viewed another way, 
intestinal P-glycoprotein expression was able to ac- 
count for almost 40% of the interpatient variation in 
CL/F not explained by variation in hepatic CYP3A4 
expression. 
The correlation with P-glycoprotein was even 
more substantial when we examined the relative 
contribution of hepatic and intestinal parameters to 
variation in cyclosporine C,,. In a stepwise regres- 
sion model, the ERMBT results were able to explain 
only 32% of the variation in C,,, whereas the 
addition of enterocyte P-glycoprotein content in- 
creased the overall predictiveness of C,, to 62% 
(Fig. 2, B). Hence, the contribution of P- 
glycoprotein expression to variation in C,, (30%) 
was essentially equal to that of liver CYP3A4 (32%). 
The variation in enterocyte P-glycoprotein was able 
to explain 44% of the variability not attributable to 
hepatic CYP3A4. The greater dependence of C,, 
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than CL/F on P-glycoprotein is logical because C,, 
largely reflects the first-pass effects of the intestine 
and liver. Clearance is more dependent than C,, 
on the elimination of cyclosporine after it has en- 
tered the systemic circulation, a process less likely to 
reflect the activity of P-glycoprotein on the lumenal 
surface of the intestine. 
Enterocyte P-glycoprotein levels were not at all 
predictive of the observed trough blood levels of 
cyclosporine. This is also consistent with the effect of 
P-glycoprotein being primarily on first-pass param- 
eters (i.e., most influencing C,,, with diminishing 
influence on blood concentrations thereafter). 
The highly significant correlations we found be- 
tween intestinal P-glycoprotein levels and cyclospor- 
ine pharmacokinetic parameters do not, in and of 
themselves, prove a causal relationship; other pos- 
sible explanations will need to be examined in future 
studies. For example, P-glycoprotein is also present 
and has variable expression in the liver.48 An impor- 
tant role for hepatic P-glycoprotein is supported by 
the observation that the administration of P- 
glycoprotein inhibitors alters the pharmacokinetics 
of intravenously administered P-glycoprotein sub- 
strates in patients.49‘51 If there is a strong correla- 
tion between intestinal and hepatic levels of P- 
glycoprotein in patients, then the potential 
contribution of liver P-glycoprotein to oral pharma- 
cokinetics would have been incorporated into our 
intestinal P-glycoprotein measurements. However, 
the fact that intestinal P-glycoprotein levels corre- 
lated only with first-pass parameters makes a sub- 
stantial liver component to our measurements less 
likely. In addition, there are recent animal data that 
offer direct evidence to support our conclusion that 
intestinal P-glycoprotein plays an important role in 
the oral absorption of P-glycoprotein substrates. 
Leu et a1.52 showed that inhibition of intestinal P- 
glycoprotein with C219 (a P-glycoprotein monoclo- 
nal antibody), 5’-adenylylimidodiphosphate (a non- 
hydrolyzable adenosine triphosphate analog), or 
quinidine (a competitive P-glycoprotein inhibitor) 
increased the absorption of etoposide from everted 
gut sacs in rats. 
We presume that P-glycoprotein functions to 
keep cyclosporine out of the body by keeping it 
within the lumen of the small bowel. This explana- 
tion would be consistent with the long-held belief 
that poor and variable absorption of cyclosporine is 
a major reason for intersubject kinetic differences.6 
The idea that P-glycoprotein and not CYP3A4 is the 
major intestinal variable in determining oral cyclo- 
sporine kinetics could account for the results of 
another recent study. Gomez et a121 noted that 
treatment with ketoconazole, a potent inhibitor of 
CYP3A4, resulted in a dramatic increase in the oral 
bioavailability of cyclosporine, estimated to exceed 
65% in healthy volunteers21 and 75% in kidney 
transplant recipients. 22 These investigators assumed 
that the only effect of ketoconazole was to inhibit 
CYP3A4 and concluded that what had been as- 
sumed to be poor absorption of the original com- 
mercial formulation of cyclosporine in fact reflected 
metabolism of cyclosporine in the intestinal wall. On 
the basis of the results of our current study, we 
expand the hypothesis for the effect of ketoconazole 
on improving the bioavailability of cyclosporine to 
include the inhibition of P-glycoprotein function. 
Ketoconazole has been shown to be a potent inhib- 
itor of P-glycoprotein in a highly drug-resistant can- 
cer cell line.53 
One should not conclude from our study that 
intestinal metabolism of cyclosporine by CYP3A4 is 
insignificant. There is now considerable data to sup- 
port the occurrence of substantial first-pass metab- 
olism of cyclosporine in human intestine.19-22 How- 
ever, our data suggests that the extent of intestinal 
metabolism of cyclosporine does not depend pri- 
marily on the level of intestinal CYP3A4. Gan et 
a1.54 recently found evidence in cultures of the hu- 
man intestinal cell line Caco-2 that P-glycoprotein 
may control the enterocyte “residence time” of cy- 
closporine and concluded that this might influence 
the extent of first-pass metabolism of cyclosporine in 
the intestine. Thus there may be complex interac- 
tions between P-glycoprotein and CYP3A4 in the 
intestine that were not evaluated in this study. 
We were unable to account for approximately one 
fourth of the variation in CL/F of cyclosporine by 
the inclusion of the ERMBT result and enterocyte 
P-glycoprotein levels into the multiple regression 
model. It seems likely that other clinical variables, 
such as variation in gastric mixing and emptying, 
lipoproteins, cholesterol, age, general health status, 
and absorption of cyclosporine (independent of P- 
glycoprotein) may account for the remaining vari- 
ability. 
It should also be noted that we found no signifi- 
cant correlation between enterocyte P-glycoprotein 
and CYP3A4, suggesting that levels of these two 
proteins do not vary coordinately, as had been pre- 
viously suggested in some cancers.55 
The demonstration of the potential role of P- 
glycoprotein in determining the CL/F of cyclospor- 
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ine may have several important clinical implications. 
First, it seems reasonable to assume that inhibition 
of P-glycoprotein may improve the oral availability 
of cyclosporine. Moreover, this strategy holds the 
potential to reduce intersubject variability in cyclo- 
sporine clearance by removing the second most im- 
portant variable (after liver CYP3A4 activity) from 
our predictive models. Second, it now seems to be 
possible that drug interactions involving cyclospor- 
ine previously ascribed exclusively to CYP3A4 inhi- 
bition (i.e., the elevation of cyclosporine blood levels 
observed when transplant patients are treated with 
imidazole antimycotic drugs or macrolide antibiot- 
ics) could, at least in part, result from inhibition of 
P-glycoprotein activity. MDR-1 messenger ribonu- 
cleic acid has also recently been shown to be induc- 
ible by some xenobiotics in a human intestinal can- 
cer cell line.56 If future studies show P-glycoprotein 
to be inducible in normal intestine as well, induction 
of P-glycoprotein could potentially account for cy- 
closporine drug interactions previously attributed to 
induction of intestinal or hepatic CYP3A4. 
In summary, our data suggest that approximately 
three-fourths of interpatient variability in the CIJF 
of cyclosporine can be attributed to just two factors: 
variation in liver CYP3A4 activity, as measured by 
the ERMBT, and variation in expression of P- 
glycoprotein in small bowel enterocytes. Whether 
our findings are applicable to the oral pharmacoki- 
netics of other P-glycoprotein substrates is an im- 
portant question for future studies. 
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